Connect Biopharma Hldgs Analyst Ratings
Connect Biopharma Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/08/2023 | 488.24% | SVB Leerink | $9 → $7 | Maintains | Outperform |
| 06/02/2022 | 320.17% | Cantor Fitzgerald | → $5 | Initiates Coverage On | → Overweight |
| 05/05/2022 | 26.05% | Piper Sandler | $25 → $1.5 | Downgrades | Overweight → Neutral |
| 05/04/2022 | 656.3% | SVB Leerink | $22 → $9 | Maintains | Outperform |
| 01/06/2022 | 1748.74% | SVB Leerink | $32 → $22 | Maintains | Outperform |
| 07/02/2021 | 2168.91% | CICC | → $27 | Initiates Coverage On | → Outperform |
| 04/13/2021 | 2168.91% | Jefferies | → $27 | Initiates Coverage On | → Buy |
| 04/13/2021 | 2589.08% | SVB Leerink | → $32 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 02/08/2023 | 488.24% | SVB Leerink | $9→$7 | 维护 | 跑赢大盘 |
| 06/02/2022 | 320.17% | 康托·菲茨杰拉德 | →$5 | 开始承保 | →超重 |
| 05/05/2022 | 26.05% | 派珀·桑德勒 | $25→$1.5 | 评级下调 | 超重→中性 |
| 05/04/2022 | 656.3% | SVB Leerink | $22→$9 | 维护 | 跑赢大盘 |
| 01/06/2022 | 1748.74% | SVB Leerink | $32→$22 | 维护 | 跑赢大盘 |
| 07/02/2021 | 2168.91% | 中金公司 | →$27 | 开始承保 | →跑赢大盘 |
| 04/13/2021 | 2168.91% | 杰富瑞 | →$27 | 开始承保 | →购买 |
| 04/13/2021 | 2589.08% | SVB Leerink | →$32 | 开始承保 | →跑赢大盘 |
What is the target price for Connect Biopharma Hldgs (CNTB)?
康乃德生物的目标价是多少？
The latest price target for Connect Biopharma Hldgs (NASDAQ: CNTB) was reported by SVB Leerink on February 8, 2023. The analyst firm set a price target for $7.00 expecting CNTB to rise to within 12 months (a possible 488.24% upside). 4 analyst firms have reported ratings in the last year.
SVB Leerink于2023年2月8日报道了康乃德生物(纳斯达克：CNTB)的最新目标价。这家分析公司将目标价定为7美元，预计CNTB将在12个月内上涨至(可能上涨488.24%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Connect Biopharma Hldgs (CNTB)?
分析师对康乃德生物的最新评级是什么？
The latest analyst rating for Connect Biopharma Hldgs (NASDAQ: CNTB) was provided by SVB Leerink, and Connect Biopharma Hldgs maintained their outperform rating.
康乃德生物(纳斯达克股票代码：CNTB)的最新分析师评级由SVB Leerink提供，康乃德生物Hldgs维持其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Connect Biopharma Hldgs (CNTB)?
新浪康乃德生物的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Connect Biopharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Connect Biopharma Hldgs was filed on February 8, 2023 so you should expect the next rating to be made available sometime around February 8, 2024.
分析师们在进行了广泛的研究后才得出股票评级，其中包括查阅公开的财务报表，与康乃德生物的高管和客户交谈，以及收听财报电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。康乃德生物Hldgs的上一次评级是在2023年2月8日提交的，因此你应该预计下一次评级将在2024年2月8日左右公布。
Is the Analyst Rating Connect Biopharma Hldgs (CNTB) correct?
分析师对新浪康乃德生物的评级正确吗？
While ratings are subjective and will change, the latest Connect Biopharma Hldgs (CNTB) rating was a maintained with a price target of $9.00 to $7.00. The current price Connect Biopharma Hldgs (CNTB) is trading at is $1.19, which is out of the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的康乃德生物Hldgs(CNTB)评级维持不变，目标价在9美元至7美元之间。康乃德生物目前的股价为1.19美元，超出了分析师的预测区间。